Skip to search formSkip to main contentSkip to account menu

emactuzumab

A humanized monoclonal antibody directed against the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R; CSF-1R; CD115), also known… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Monoclonal Antibodies

Narrower (1)

RG7155
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Therapeutically-induced stable disease in oncology early clinical trials
Rationale The RECIST guideline defines four categories of response to treatment for cancer patients according to post-baseline… 
2019
2019
Periorbital oedema secondary to emactuzumab treated with topical 2.5% phenylephrine
Periorbital oedema (POE), a condition with vision-impairing potential, is an adverse effect of several immunotherapies. We… 
2019
2019
Tumor biological characteristics of Vestibular Schwannoma
The aim of this thesis is to shed light on the biological background of progression of sporadic vestibular schwannomas. The… 
2018
2018
Effects of IL‐10 and Th2 cytokines on human Mφ phenotype and response to CSF1R inhibitor
Tumor‐associated Mφs display a plastic phenotype that is regulated by the local tumor milieu. Gene expression analysis and… 
Review
2018
Review
2018
Advances in treatment for tenosynovial giant cell tumors
ABSTRACT Introduction: Tenosynovial giant cell tumor (TGCT) is a benign clonal neoplastic proliferation arising from the synovium… 
2015
2015
Tumor macrophage target fuels $1.7-billion deal
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)